10% PROMISSORY NOTEConvertible Security Agreement • September 18th, 2023 • Regen BioPharma Inc • Pharmaceutical preparations • Nevada
THIS IS A 10% PROMISSORY NOTE of Regen Biopharma, Inc., a Nevada corporation (the “Company”), having its principal place of business at 4700 Spring Street suite 304 La Mesa, CA 91942 (this “Note”), which represents a duly authorized and validly issued debt of the Company.
ContractUnit Purchase Agreement • May 5th, 2017 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ whose address is _____________.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 4, 2024, between REGEN BIOPHARMA, INC, a Nevada corporation (the “Company”), and Coventry Enterprises, LLC, a Delaware limited liability company (the “Investor”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • Nevada
AGREEMENT BY AND BETWEEN KCL THERAPEUTICS, INC. AND ONCOLOGY PHARMA INC.License Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT, including the exhibits referred to herein and attached hereto (the “Agreement”), effective as of April 7, 2021 (the “Effective Date”), is made and entered into by and between KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen BioPharma Inc. (“Licensor”) and Oncology Pharma, Inc., a Nevada corporation (“Licensee”). Licensor and Licensee may be referred to in this Agreement each as a “Party” or collectively as the “Parties.”
10% PROMISSORY NOTESecurity Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations • Delaware
THIS IS A 10% PROMISSORY NOTE of Regen Biopharma, Inc., a Nevada corporation (the “Company”), having its principal place of business at 4700 Spring Street, Suite 304, La Mesa, California 91942 (this “Note”), which represents a duly authorized and validly issued debt of the Company.
ContractCollateralized Secured Promissory Note • February 12th, 2019 • Regen BioPharma Inc • Pharmaceutical preparations
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. LENDERS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.
EMPLOYMENT AGREEMENT BETWEEN REGEN BIOPHARMA, INC AND CHRISTINE ICHIMEmployment Agreement • January 22nd, 2015 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (the "Agreement") dated as of January 14, 2015 is entered into between Regen BioPharma, Inc., a Nevada corporation, (the "Company") and Christine Ichim ("Employee").
ContractSecurities Purchase Agreement • January 14th, 2014 • Regen BioPharma Inc • Pharmaceutical preparations • California
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of , by and between Regen Biopharma, Inc. , a Nevada corporation, with headquarters located at 4700 Spring Street, Suite 304,La Mesa California, 91942, (the “Company”), and ASC Recap LLC, a Connecticut Limited Liability Company, with its address at 90 Grove Street, Suite 108, Ridgefield CT 06877(the “Buyer”).
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC.License Agreement • September 16th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations
THIS LICENSE AGREEMENT, including the exhibits referred to herein and attached hereto (the “Agreement”), effective as of June 23, 2015 (the “Effective Date”), is made and entered into by and between Regen BioPharma Inc., an Nevada corporation (“Licensor”) and Zander Therapeutics Inc., a Nevada corporation (“Licensee”). Licensor and Licensee may be referred to in this Agreement each as a “Party” or collectively as the “Parties.”
UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC.Unit Purchase Agreement • November 24th, 2015 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ whose address is _____________.
EMPLOYMENT AGREEMENT BETWEEN REGEN BIOPHARMA, INC. AND TODD S. CAVENEmployment Agreement • February 13th, 2015 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (the "Agreement") dated as of February 11, 2015 is entered into between Regen BioPharma, Inc., a Nevada corporation, (the "Company") and Todd S. Caven ("Employee").
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND SANTOSH KESARIConsulting Agreement • June 30th, 2015 • Regen BioPharma Inc • Pharmaceutical preparations • California
Agreement by and between Santosh Kesari (“Consultant”) , a natural person whose address is at 3525 Del Mar Heights Road #133, San Diego CA 92130 and Regen Biopharma, Inc. (“Company”) , a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942.
AMENDMENT TO EMPLOYMENT AGREEMENT BY AND BETWEEN TODD S. CAVEN AND REGEN BIOPHARMA, INC February 11, 2015Employment Agreement • March 14th, 2017 • Regen BioPharma Inc • Pharmaceutical preparations
WHEREAS, Todd S. Caven ( “Employee”) and Regen Biopharma, Inc. a Nevada corporation, (“Company”) have entered into that Employment Agreement (“Employment Agreement”) dated as of February 11, 2015.
Investor Relations Consulting Agreement Between Regen Biopharma Inc. And Synergy Business Consultants LLCInvestor Relations Consulting Agreement • May 5th, 2017 • Regen BioPharma Inc • Pharmaceutical preparations • California
This document acts forth the agreement Regen Biopharma Inc. (“the Company”) and Synergy Business Consultants LLC concerning Investor Relation and Financial Public Relation services rendered to the Company from February 24, 2017 and continuing through March 24, 2017. (1 month).
AMENDMENT TO SUBLEASE AGREEMENT (“AGREEMENT”) ENTERED INTO OCTOBER 1, 2014 BY AND BETWEEN ENTEST BIOMEDICAL, INC. ( “SUBLESSOR”) AND REGEN BIOPHARMA,INC (“SUBTENANT”)Sublease Agreement • January 22nd, 2015 • Regen BioPharma Inc • Pharmaceutical preparations
ContractBusiness Advisory Board Services Agreement • January 5th, 2018 • Regen BioPharma Inc • Pharmaceutical preparations • California
This Business Advisory Board Services Agreement (the "Agreement"), dated October 16, 20I 7, is entered into between Regen BioPharma, Inc., a Nevada corporation ("the Company"), and JP Millon an individual with a principal place of residence (“'Candidate").
SUBLEASE AGREEMENTSublease Agreement • December 18th, 2014 • Regen BioPharma Inc • Pharmaceutical preparations
This is an agreement to sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 according to the terms specified below.
EMPLOYMENT AGREEMENT BETWEEN REGEN BIOPHARMA, INC. ANDEmployment Agreement • October 13th, 2015 • Regen BioPharma Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (the "Agreement") dated as of October 9, 2015 is entered into between Regen BioPharma, Inc., a Nevada corporation, (the "Company") and Harry M. Lander ("Employee").
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC. Dated December 15, 2017License Agreement • January 5th, 2018 • Regen BioPharma Inc • Pharmaceutical preparations • California
WHEREAS, REGEN BIOPHARMA, INC. (“REGEN”) AND ZANDER THERAPEUTICS, INC. (“ZANDER”) ARE PARTIES TO THAT AGREEMENT DATED JUNE 23, 2015 WITH ZANDER WHEREBY REGEN GRANTED TO ZANDER AN EXCLUSIVE WORLDWIDE RIGHT AND LICENSE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANY AND ALL INTELLECTUAL PROPERTY CONTROLLED BY REGEN (“LICENSE AGREEMENT”).
WORLDWIDE INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT DATED May 1, 2013 This Intellectual Property Assignment Agreement (“Agreement”) is entered into on May 1, 2013 by and between Dr. Wei Ping Min (“Assignor”), an individual residing at 84 Hesketh St,...Intellectual Property Assignment Agreement • October 15th, 2013 • Regen BioPharma Inc
AMENDMENT TO LICENSE AGREEMENT DATED APRIL 6, 2015License Agreement • August 26th, 2015 • Regen BioPharma Inc • Pharmaceutical preparations
Benitec Australia Limited, an Australian corporation (ACN 080 299 645) having its registered office at 1-15 Barr Street, Balmain, NSW, Australia 2041, (“Benitec Australia”) and Regen BioPharma, Inc., a United States company having its registered office at 4700 Spring Street, Suite 304, La Mesa, CA 91942 USA, (“Regen BioPharma”)entered into a license agreement ( the “Agreement”) on August 5, 2013. Benitec Australia and Regen BioPharma may be referred to in this Agreement each as a “Party” or collectively as the “Parties.”
SUBLEASE AGREEMENTSublease Agreement • April 29th, 2024 • Regen BioPharma Inc • Pharmaceutical preparations
This is an agreement to sublet office space located at 4 700 Spring Street, Suite 304, La Mesa, California 9 I 942 according to the terms specified below.
AGREEMENT BY AND BETWEEN KCL THERAPEUTICS, INC. AND HARRY LANDERConsulting Agreement • January 25th, 2019 • Regen BioPharma Inc • Pharmaceutical preparations • California
Agreement made on made on January 23, 2019 by and between Harry Lander (“Consultant”), a natural person whose address is at 36 Robinson Road, #13-01, Singapore and KCL Therapeutics, Inc. (“Company”), a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred to individually as “Party” and collectively as “Parties”.
LICENSE AGREEMENT - EXECUTIONLicense Agreement • October 15th, 2013 • Regen BioPharma Inc • New South Wales
THIS LICENSE AGREEMENT, including the exhibits referred to herein and attached hereto (the “Agreement”), effective as of August 5, 2013 (the “Effective Date”), is made and entered into by and between Benitec Australia Limited, an Australian corporation (ACN 080 299 645) having its registered office at 1-15 Barr Street, Balmain, NSW, Australia 2041, (“Benitec Australia”) and Regen BioPharma, Inc., a United States company having its registered office at 4700 Spring Street, Suite 304, La Mesa, CA 91942 USA, (“Regen BioPharma”). Benitec Australia and Regen BioPharma may be referred to in this Agreement each as a “Party” or collectively as the “Parties.”
SERVICE AGREEMENTIndependent Contractor Agreement • October 15th, 2013 • Regen BioPharma Inc • California
This Independent Contractor Agreement (“Agreement”) is entered into this 27th day of July 2013 between Dr. Wei Ping Min (“Min”), a research scientist (hereinafter referred to as “Contractor”) whose address is 84 Hesketh Street, London Ontario N6G5H5, Canada and Regen BioPharma, Inc. (hereinafter referred to as “Client”), a Nevada corporation with offices at 4700 Spring Street, Suite 304, La Mesa, CA 91942.
July 1, 2016 David Koos Chairman & CEO Regen BioPharma Inc. (RGBP) La Mesa, CA 91942 Delivered: 07/01/2016 Via email to: David Koos david.koos@regenbiopharma.com Dear David,Investment Banking Engagement Agreement • July 7th, 2016 • Regen BioPharma Inc • Pharmaceutical preparations
The purpose of this investment banking engagement agreement (the "Agreement") is to set forth the terms and conditions pursuant to which CIM Securities, LLC ("CIM"), a FINRA member in good standing, shall act as exclusive financial advisor and placement agent for Regen BioPharma Inc. (RGBP, RGBPP) (“Company”), a Nevada Corporation and all affiliates (also the "Company") and introduce the Company to one or more accredited investors (“Investors”) in connection to a proposed private placement (the "Private Placement") of equity and / or debt securities (the "Securities") of the Company for the capital needed to continue research and development on four blocker compounds. However, CIM specifically acknowledges that the Company has retained Objective Capital Partners, located in San Diego, California, to identify potential strategic partners for the Company, which could result in an infusion of capital that does not involve the sale of debt or equity securities. The gross proceeds from the
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND THOMAS ICHIMConsulting Agreement • November 5th, 2015 • Regen BioPharma Inc • Pharmaceutical preparations • California
Agreement made on November 2. 2015 by and between Thomas Ichim (“Consultant”) , a natural person whose address is at 9255 Towne Centre Drive #450 San Diego CA 91211 and Regen Biopharma, Inc. (“Company”) , a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred to individually as “Party” and collectively as “Parties”.
Exclusive License Agreement Between OHSU and Regen BioPharma, INC For Invention Disclosure 0472Exclusive License Agreement • October 15th, 2013 • Regen BioPharma Inc • Oregon
This Exclusive License Agreement (this "Agreement"), dated and effective as of June 5, 2013 (the "Effective Date"), is between the Oregon Health & Science University, having offices at 0690 SW Bancroft Street, L106TT, Portland, Oregon 97239 ("OHSU"), and Regen BioPharma, Inc., having offices at 4700 Spring St # 304, La Mesa, CA 91942 ("Licensee"). OHSU and Licensee are herein referred to each as a "Party" and collectively as the "Parties."
Agreement made this 5th day of August 2016 by and between Regen Bioparma, Inc. (“Company”) and David R. Koos (“Koos”)Employment Agreement • December 21st, 2016 • Regen BioPharma Inc • Pharmaceutical preparations • California
WHEREAS, On February 13, 2015 Koos was issued Nine Million of the Company’s Common Shares (“Compensation Common Shares”) pursuant to that employment agreement entered into by and between Koos and the Company on February 11, 2015 ( “Employment Agreement”)
Consulting AgreementConsulting Agreement • November 25th, 2014 • Regen BioPharma Inc • Pharmaceutical preparations • California
Agreement by and between Christine Ichim (“Consultant”) , a natural person whose address is at 12685 Campo Road, Spring Valley CA 91978 and Regen Biopharma, Inc. (“Company”) , a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942.
EMPLOYMENT AGREEMENT BETWEEN BIO-MATRIX SIENTIFIC GROUP, INC. ANDEmployment Agreement • October 15th, 2013 • Regen BioPharma Inc • California
is entered into between Bio-Matrix Scientific Group, Inc., a Delaware corporation, (the "Company") and J. Christopher Mizer ("Employee").
AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND MOHAMMAD HARIS, PH.D.Scientific Advisory Board Agreement • January 19th, 2023 • Regen BioPharma Inc • Pharmaceutical preparations
Agreement made on November 22, 2022, by and between MOHAMMAD HARIS (“Scientific Advisory Board Member” also referred to as ”SAB Member ”), a natural person whose address is___________, and Regen BioPharma, Inc. (“Company”), a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. SAB Member and Company may be referred to individually as “Party” and collectively as “Parties”.
SETTLEMENT AND RELEASE AGREEMENTSettlement Agreement • September 24th, 2021 • Regen BioPharma Inc • Pharmaceutical preparations • California
This Settlement and Release Agreement (the "Agreement") is entered into by and between CHEMDIV, INC. ("Chemdiv"), REGEN BIOPHARMA, INC. ("Regen"), ZANDER THERAPEUTICS, INC., and DAVID KOOS ("Koos"). Regen, Zander, and Koos may sometimes be collectively referred to herein as "Defendants." Chemdiv and Defendants are sometimes collectively referred to herein as the "Parties."
SOW Number FWO2-CRO Gap Assessment SOW Effective Date 10/11/2021 SOW Termination Date 11/15/2021 Master Agreement Master Services Agreement dated as of 5/12/2021Scope of Work Order • October 19th, 2021 • Regen BioPharma Inc • Pharmaceutical preparations
